Expression and Clinicopathological Significance of Mel-18 and Bmi-1 in Esophageal Squamous Cell Carcinoma

Huaijun Ji, MM1, Ming Cao, MD2, Kunlun Ren, MM1, Ningbo Sun, MM3, Wei Wang, MD2, Qiang Zhu, MD2, Qi Zang, MM2, and Zhongmin Jiang, MD2

Abstract
The Polycomb group genes are a general class of regulators that are responsible for maintaining homeotic gene expression throughout cell division. Polycomb group expression plays an important role in oncogenesis of several types of human cancer. Melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 are key Polycomb group proteins. Studies have shown that melanoma nuclear protein 18 is a potential tumor suppression, and B-cell-specific Moloney leukemia virus insert site 1 is overexpressed in several human malignancies. However, the roles of melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 in esophageal squamous cell carcinoma are still unclear. In this study, we analyzed the expression levels of melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 in 89 esophageal cancer tissues and paired normal mucosal tissues using immunohistochemistry, Western blotting, and quantitative real-time polymerase chain reaction analyses. We found that the expression of melanoma nuclear protein 18 in the carcinoma tissues was significantly lower than that in the noncancerous mucosal tissues (P < .05), and B-cell-specific Moloney leukemia virus insert site 1 expression in the carcinoma tissues was significantly higher than that in the noncancerous mucosal tissues (P < .05). In addition, the expression of melanoma nuclear protein 18 was correlated with clinical stage, depth of invasion, and lymph node metastasis (P < .05) but was not correlated with gender, age, degree of differentiation, or disease-free survival (P > .05). B-cell-specific Moloney leukemia virus insert site 1 expression was strongly correlated with the degree of differentiation, clinical stage, and lymph node metastasis (P < .05) but was not correlated with the gender, age, depth of invasion or disease-free survival (P > .05). Moreover, there was a negative correlation between melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 expressions in esophageal squamous cell carcinoma (P < .05). Our study suggests that melanoma nuclear protein 18 and B-cell-specific Moloney leukemia virus insert site 1 may play a crucial role in esophageal squamous cell carcinoma. Melanoma nuclear protein 18 or B-cell-specific Moloney leukemia virus insert site 1 may be a potential biomarker for diagnosis and prognosis of esophageal squamous cell carcinoma.

Keywords
esophageal squamous cell carcinoma, Polycomb group protein, Mel-18, Bmi-1, immunohistochemistry, Western blot, real-time PCR

Abbreviations
Bmi-1, B-cell-specific Moloney leukemia virus insert site 1; Ct, comparative threshold; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; Mel-18, melanoma nuclear protein 18; PcG, Polycomb group; PRC1, Polycomb repressive complex 1; PRC2, Polycomb repressive complex 2.

Introduction
Esophageal malignancy is one of the most lethal cancers worldwide. It comprises approximately 7% in all gastrointestinal cancers internationally.1 Despite clinical advances in the field of oncology, esophageal cancer has the sixth highest mortality of all cancers, with 406,800 deaths per year.2 Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancer. Smoking and drinking are the major risk factors for ESCC.3-5 Alcohol consumption and smoking are independently related to ESCC incidence and might synergistically increase the risk.6-9 In addition, genetic factors are also associated with increased risk of ESCC development.10-13 Microsatellite instability (MSI) is a hallmark of many tumors, including colorectal, gastric, and endometrial cancers; however, ESCC has shown no MSI.14-16 Melanoma nuclear protein 18 (Mel-18) and B-cell-specific Moloney leukemia virus insert site 1 (Bmi-1) are key Polycomb group proteins and play important roles in the regulation of gene expression throughout cell division.17-20 As potential tumor suppressors, Mel-18 and Bmi-1 have been implicated in ESCC development through genetic changes, such as homozygous deletion, amplification, and mutation.21-24 In the present study, the expression levels of Mel-18 and Bmi-1 were evaluated in 89 esophageal cancer tissues and paired normal mucosal tissues using immunohistochemistry, Western blotting, and quantitative real-time polymerase chain reaction analyses. Our results revealed that the expression of Mel-18 in the carcinoma tissues was significantly lower than that in the noncancerous mucosal tissues (P < .05), whereas Bmi-1 expression in the carcinoma tissues was significantly higher than that in the noncancerous mucosal tissues (P < .05). Moreover, the expression of Mel-18 was correlated with clinical stage, depth of invasion, and lymph node metastasis (P < .05), whereas Bmi-1 expression was strongly correlated with the degree of differentiation, clinical stage, and lymph node metastasis (P < .05). Furthermore, there was a negative correlation between Mel-18 and Bmi-1 expressions in esophageal squamous cell carcinoma (P < .05). These findings suggest that Mel-18 and Bmi-1 may play a crucial role in ESCC development and could be potential biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma.
factors for ESCC. Esophageal squamous cell carcinoma is a highly aggressive malignancy due to late diagnosis, rapid progression, and poor prognosis. Thus, the rate of the mortality of esophageal cancer is similar to the rate of the incidence. The 5-year survival rate of esophageal cancer is less than 20%. However, the overall survival could be dramatically improved by early diagnosis, with a 5-year survival rate of up to 90%. The majority of patients with early ESCC show no clinical symptoms and manifestations. Therefore, identifying ideal markers with high sensitivity and specificity will provide physicians with valuable information for diagnosis and suitable treatment options. At present, there are no suitable biomarkers for diagnosing ESCC; thus, finding specific biomarkers of ESCC is urgently needed to detect tumors and recurrence.

The Polycomb group (PcG) genes are involved in the regulation of the cell cycle, hematopoiesis, and X-inactivation. Polycomb group gene expression plays an important role in oncogenesis of various types of human cancer. Melanoma nuclear protein 18 (Mel-18) and B-cell-specific Moloney leukemia virus insert site 1 (Bmi-1) are key PcG proteins, and they are highly similar in structure. Melanoma nuclear protein 18 and Bmi-1 play important roles in oncogenesis and progression of ESCC; however, the effects of Mel-18 and Bmi-1 are different in cancer cell growth and survival. Previous studies have shown that Mel-18 is overexpressed in several human tumors, including Hodgkin's lymphomas, human melanoma, and medulloblastoma. Recently, several reports have suggested that Mel-18 may act as a tumor suppressor restraining c-Myc expression in oncogenesis and progression of ESCC. Thus, the function of Mel-18 in cancers is still unclear. The Bmi-1 gene was discovered in 1999, and overexpression of Bmi-1 has been found in a variety of human cancers, such as breast cancer, gastric cancer, and head and neck cancer, and its expression was also associated with the development of tumors. Studies have shown that the expression of Mel-18 is negatively correlated with Bmi-1 in several tumors. However, the functions of Mel-18 and Bmi-1 in ESCC have not been fully elucidated. Therefore, we investigated the expression levels of the 2 marks in esophageal cancer tissues and paired normal mucosal tissues, and our study suggests that Mel-18 or Bmi-1 may be a biomarker for diagnosis and prognosis of ESCC.

Materials and Methods

Sample Preparation of Patient With ESCC

The samples of esophageal cancer tissue and adjacent noncancerous mucosal tissue were obtained from 29 patients who received the surgical treatment from 2015 to 2016 in our hospital. Normal tissues located 5 cm away from the tumor edge were collected during the surgery. Tissue microarrays containing 60 esophageal tissue, and adjacent normal tissue sections were commercially obtained from Chaoying Bioscience (Shanxi, China). None of the patients received prior chemotherapy or radiotherapy before the surgery. Pathology of the esophageal cancer biopsies showed they were all squamous cell carcinomas. The patient information, including gender, age, and clinicopathological characteristics, was obtained from the medical records or the manufacturer. The enrolled patients included 64 males and 25 females, and the median age was 59 years (range: 36-76 years). The median follow-up time was 13.8 months (range: 5.0-22.9 months). The duration of disease-free survival (DFS) began at the day of surgery and ended at relapse, metastasis, last follow-up, or death for any cause. Patients consented to the specimen collection, and this study was approved by the research ethics committee of our hospital (Qianfoshan Hospital affiliated with Shandong University).

Quantitative Real-Time-PCR Assays

Total RNA was extracted from frozen tissue specimens using Total RNA Kit II (Omega, Georgia). One microgram of total RNA was used to perform reverse transcription for first-strand cDNA using the Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, Massachusetts). Subsequently, quantitative PCR was performed in triplicate on an ABI VIIA7 Real-Time PCR System (Applied Biosystems, Foster City, California) with SuperReal PreMix Plus (SYBR Green; TIANGEN, Beijing, China). The following gene-specific primer pairs were used: Mel-18: (F) 5'-CGGACTACAGGATCAAAATCA-3', (R) 5'-GGGTTCATGAATACCCG-3'; Bmi-1: (F) 5'-CCACCTGATGTGTGCTTTG-3', (R) 5'-TTTCAATGTCGTTGCTTTG-3'. β-Actin: (F) 5'-GACACACCTCTACAATGAG-3', (R) 5'-GCTACACCTCCCTCGTAGATGG-3'. All reactions were performed in a 20 μl reaction volume. Polymerase chain reaction was carried out after predenaturing at 95°C for 15 minutes followed by 40 cycles at 95°C for 10 seconds and 62°C for 32 seconds. Gene expression was analyzed with the comparative threshold (Ct) cycle method after normalizing to β-Actin. ΔΔCt = ΔCt (esophageal cancer)-ΔCt (control) for RNA samples. The fold change for each esophageal cancer sample relative to the control sample = 2^-ΔΔCt. When the expression showed a 2-fold increase or decrease compared to the normal counterpart tissue, it was considered altered expression.

Immunohistochemistry Staining

Tissue samples were soaked in 10% neutral buffered formalin, embedded in conventional paraffin, and sectioned to a thickness of approximately 3 μm. After deparaffinization, the specimens were hydrated and incubated with an epitope retrieval solution (pH 6.0) in a microwave (temperature controlled at 95°C-100°C) for 20 minutes. The slices were then incubated with 0.3% H2O2 for 10 minutes at room temperature to inactivate endogenous peroxidase and rinsed with phosphate-buffered saline. Then, the specimens were incubated with rabbit polyclonal antibody for Mel-18 (1:300 dilution, bs-9673 R, Bioss, Beijing, China) and rabbit polyclonal antibody for Bmi-1 (1:500 dilution, ab85688, Abcam) at 4°C overnight. After that, the specimens were incubated with secondary antibodies using an Elivision Plus Kit (Maixin-Bio; Lab
Vision, Kalamazoo, Michigan). DAB (Diaminobenzidine) (DaKo, Carpinteria, California) chromogenic reagent was added. After the specimens were counterstained with hematoxylin, they were dehydrated, mounted, and observed with a Nikon 50i fluorescence microscope (Nikon, Tokyo, Japan).

The immunohistochemical specimens were observed under 200× optical microscope and evaluated using positive staining intensity and percentage of positive staining by 2 pathologists. The extent of the stained cells was graded as follows: 0%-5.0% = 0, 5.1%-25.0% = 1, 25.1%-50.0% = 2, 50.1%-75.0% = 3, and 75.1%-100% = 4. Positive staining intensity was rated as follows: no staining = 0, light yellow = 1, yellow = 2, and dark yellow = 3. The final score was determined by multiplying the positivity scores with the staining intensity scores of cells; a score of 0 to 2 was regarded as negative (−), 3 to 5 as weak (+), 6 to 8 as moderate (++) and 9 to 12 as strong (++++).

**Western Blot**

Human esophageal cancer tissues and adjacent noncancerous mucosal tissue were homogenized and centrifuged at 12 000g for 30 minutes at 4°C. The protein concentrations were determined using the BCA (Bicinchoninic Acid) Protein Assay Kit (BOSTER, Wuhan, China). Thirty micrograms of total protein was separated by 10% SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis), transferred to a PVDF (Polyvinylidene Fluoride) membrane, and blocked in 5% milk. The membranes were incubated with rabbit polyclonal antibody for Mel-18 (1:500 dilution, bs-9673 R, Bioss, Beijing, China) and rabbit polyclonal antibody for Bmi-1 (1:8000 dilution, ab85688, Abcam) or GAPDH (Glyceraldehyde Phosphate Dehydrogenase) (1:6000 dilution, China) at 4°C overnight. The secondary antibody (1:8000 dilution, China) was incubated with the membrane for 1 hour at room temperature. Finally, the immunoreactive protein bands were visualized with a chemiluminescence kit (Millipore, MA, USA).

**Statistical Analysis**

The protein expression data were statistically analyzed with χ² tests and Fisher exact test. The expression levels of Mel-18 and Bmi-1 messenger RNA (mRNA) expression levels was analyzed by Pearson coefficient test. Disease-free survival rates were plotted using the Kaplan-Meier method, and the log-rank test was used for analysis. All statistical analyses were performed using the SPSS 21.0 software package. P < .05 was considered statistically significant.

**Results**

**Immunodetection of MEL-18 and BMI-1 in ESCC Tissues**

The expression rate of Mel-18 in ESCC tissues and normal mucosa was 33.7% (30 of 89) and 68.5% (61 of 89), respectively. The expression rate of Bmi-1 in ESCC tissues and normal mucosa was 74.2% (66 of 89) and 30.3% (27 of 89), respectively. The differences in the expression of Mel-18 and Bmi-1 were statistically significant between esophageal cancer tissues and normal esophageal mucosa (χ² = 21.606, P < .05; χ² = 34.249, P < .05). In our cases, Mel-18 and Bmi-1 were expressed in the nuclei of tumor cells as shown by immunohistochemistry staining (Figure 1).

**The Association Between the Expression of MEL-18 and BMI-1 With Clinicopathological Parameters**

The importance of Mel-18 and Bmi-1 in ESCC was evaluated by correlating their expression levels with clinicopathological features. Several of the analyzed characteristics showed significant associations with the expression levels (Table 1). The results showed that the expression of Mel-18 was correlated with clinical stage, depth of invasion, and lymph node metastasis but not with patient gender, age, or degree of differentiation. The expression of Bmi-1 was correlated with degree of differentiation, clinical stage, and lymph node metastasis but not with patient gender, age, or depth of invasion.

**Quantifying MEL-18 and BMI-1 Expression Levels by Western Blot Analysis and Real-Time PCR**

Melanoma nuclear protein 18 and Bmi-1 protein levels were quantified by Western blot analyses. The proteins were detected in ESCC and corresponding para-carcinoma tissues. Compared to the para-carcinoma tissues, the expression level of Mel-18 was significantly lower, and Bmi-1 was significantly higher in ESCC with statistically significant differences (P = .028 and P = .008, respectively, paired-sample test; Figure 2). Transcription of Mel-18 and Bmi-1 was quantified by quantitative real-time PCR. The results show that Mel-18 mRNA was downregulated in 16 (55.17%) of 29 esophageal tumor tissues (<0.5-fold), and Bmi-1 mRNA was overexpressed in 18 (62.07%) of 29 esophageal tumor tissues (>2-fold). The ESCC tissues exhibited a lower level of Mel-18 mRNA and a higher level of Bmi-1 mRNA than the para-carcinoma tissues.

**Association of MEL-18 and BMI-1 With Survival Outcome**

We also analyzed the association between the expression of Mel-18 and Bmi-1 with patient survival. By the end of the study, 4 patients had relapsed and 1 patient had died from ESCC. The median DFS time was 20.4 months (95% CI: 18.5-22.4 months). Kaplan-Meier analysis shows that there was no significant correlation between the expression of Mel-18 and Bmi-1 with DFS (P > .05; Figure 3).
significant negative correlations between Mel-18 and Bmi-1 ($r = -0.285$, $P = 0.007$, $\chi^2$ test; Table 2).

**Discussion**

Mammalian Pcg proteins are classified into Polycomb repressive complexes 1 and 2 (PRC1 and PRC2). Melanoma nuclear protein 18, a member of the PRC1, is detected in a number of tumor and normal tissues. Melanoma nuclear protein 18 was reported to be overexpressed in several tumors, including breast, colorectal, prostate, and gastric cancers.
Therefore, these results suggest that Mel-18 plays an oncogenic or tumor-suppressor role possibly depending upon the context of the cancer system. In our study, the expression of Mel-18 was significantly reduced in ESCC tissues compared to the corresponding noncancerous mucosal tissues. We found a negative correlation between the expression of Mel-18 and the clinical stage, depth of cancer invasion (T classification), and lymph node metastasis (N classification) with statistically significant differences ($P < .05$). These results suggest that Mel-18 protein is associated with carcinogenesis, progression, and metastasis. Thus, Mel-18 may play a crucial role in ESCC.

B-cell-specific Moloney leukemia virus insert site 1 is structurally highly similar to Mel-18, is another important member of PRC1, regulates proliferation and senescence in mammalian cells. It displays an inverse correlation with Mel-18 and was identified as an oncogene. It has been reported to be negatively regulated by Mel-18 via repression of the c-Myc. Overexpression of Bmi-1 in esophageal cancer has been previously reported. In this study, we found that Bmi-1 plays an important role in ESCC progression. We demonstrated that Bmi-1 expression was significantly upregulated in ESCC tissues compared to adjacent noncancerous tissues. In addition, we also observed that positive expression of Bmi-1 was correlated with the clinical stage, degree of differentiation, and lymph node metastasis (N classification), and the differences were statistically significant ($P < .05$). These results suggest that Bmi-1 protein may play a crucial role in the carcinogenesis, progression, and metastasis of ESCC. However, there was no correlation between Bmi-1 expression and depth of cancer invasion or DFS, which was not consistent with the results of a previous study. He et al reported an association between Bmi-1 overexpression and poor OS (Overall Survival). However, Hwang et al and Choy et al found no association between Bmi-1 expression and OS in patients with ESCC consistent with the results of the present study. One of the reasons may be that the small number of samples. Previous studies have shown that the expression of Bmi-1 was no significant associations with age, gender, tumor diameter, or nationality.

The molecular pathways by which these proteins regulate oncogenesis remain unclear. B-cell-specific Moloney leukemia virus insert site 1 can inhibit the INK4a-ARF gene and participate in the development of a variety of tumors. B-cell-specific Moloney leukemia virus insert site 1 can promote self-renewal and differentiation in liver cells, improve leukemia stem cell proliferation, and is involved in the proliferation of tumor cells under the synergy of the c-Myc gene. B-cell-specific Moloney leukemia virus insert site 1 has been reported to be negatively regulated by Mel-18 via repression of the c-Myc oncogene, which is amplified and/or overexpressed in a variety of malignancies. Lee et al reported that Mel-18 expression was reduced in breast cancer cells and tissues and upregulated the expression of Mel-18 and c-Myc. Thus, Bmi-1 levels were decreased, reducing the activity of PKB/Akt in breast cancer cells, accelerating ageing and decreasing the life of cells, and inhibiting tumor growth. Wang et al found a significant negative correlation between the expression of Mel-18 and c-Myc in prostate cancer. Zhang et al found that Mel-18 also had lower expression in gastric cancer tissues and cells; overexpression of Mel-18 decreased Bmi-1 expression and upregulated p16, eventually inhibiting the growth of gastric cancer cells.

In the study, we demonstrated that neoplastic ESCC cells show abnormal expression of Mel-18 and Bmi-1. We propose that abnormal PcG expression alters the expression of
target genes involved in regulation of senescence or the cell cycle in an altered composition of the PRC1 in ESCC. Our observations add to the increasing evidence that PcG genes are important contributors to carcinogenesis and progression of human tumors. We additionally found that there was a strong negative correlation between Mel-18 and Bmi-1 expressions at the mRNA \( (r = -0.592, P = .001) \) and protein level \( (r = -0.285, P = .007) \). The underlying mechanism of Mel-18 and Bmi-1 may be through the regulation of c-myc.

Table 2. Relationship Between the Expression of Mel-18 and Bmi-1 in Esophageal Cancer.

| Mel-18 | BMI-1 |
|--------|-------|
| +      | 17    | 13 |
| -      | 49    | 10 |

Abbreviations: Bmi-1, B-cell-specific Moloney leukemia virus insert site 1; Mel-18, melanoma nuclear protein 18. There were significant negative correlations between Mel-18 and Bmi-1 \( (r = -0.285, P = 0.007; \chi\text{-square test}).\)

This study is the first to investigate the correlation between Mel-18 expression level and clinicopathological characteristics in ESCC. The expression of Mel-18 and Bmi-1 was correlated with esophageal cancer progression. Advanced-stage ESCC is more likely to express lower Mel-18 and higher Bmi-1. We examined associated gene expression, but we did not investigate the detailed mechanisms of regulation of esophageal cancers. The molecular pathways through which these genes regulate oncogenic signals need to be further studied in ESCC.

Conclusion

In conclusion, we observed an inverse correlation between the expression levels of Mel-18 and Bmi-1 in ESCC. Both Mel-18 and Bmi-1 are involved in the development and progression of ESCC. Melanoma nuclear protein 18 and Bmi-1 might be novel molecular markers for ESCC. However, the detailed mechanisms of regulation of Mel-18 and Bmi-1 remained to be elucidated.

Acknowledgments

The authors would express our outmost gratitude to all the personnel’s in the Medical Research Center, Qianfoshan Hospital, Shandong Medical University for their excellent technical assistance.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Ministry of Science and Technology Research Foundation for funding support (2013GSF11836).

References

1. Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther. 2015;15(10):1157-1169.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.

4. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165(12):1424-1433.

5. Baan R, Straif K, Grosse Y, et al. WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8(4):292-293.

6. Crew KD. Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):450-464.

7. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-239.

8. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos. CA Cancer J Clin. 2012;62(5):283-298.

9. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64(1):9-29.

10. Zhou SL, Wang LD. Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol. 2010;16(19):2348.

11. Heard E. Recent advances in X-chromosome inactivation. Curr Opin Cell Biol. 2004;16(3):247-255.

12. Raaphorst FM, Otte AP, van Kemenade FJ, et al. Distinct BMI-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, c-Myc oncoproteins. J Biol Chem. 2007;282(32):20021-20026.

13. He XT, Cao XF, Ji L, et al. Association between Bmi1 and clinicopathological features. Clin Cancer Res. 2010;16(23):6929-6936.

14. Zhang XW, Sheng YP, Li Q, et al. Bmi1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer. 2010;9:40.

15. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. J Immunol. 2001;166(10):5925-5934.

16. Tagawa M, Sakamoto T, Shigemoto K, et al. Characterization and chromosomal localization of the human polycomb group oncogenes in human malignant lymphomas and epithelial tumours. Hum Mol Genet. 2005;14(spec no 1): R93-R100.

17. Zhang XY, Sheng YP, Li Q, et al. Bmi1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer. 2010;9:40.

18. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. J Immunol. 2001;166(10):5925-5934.

19. Raaphorst FM. Deregulated expression of polycomb-group oncogenes in human malignant lymphomas and epithelial tumours. Hum Mol Genet. 2005;14(spec no 1): R93-R100.

20. Zhang XY, Sheng YP, Li Q, et al. Bmi1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer. 2010;9:40.

21. Lu YW, Li J, Guo WJ. Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma. J Exp Clin Cancer Res. 2010;29:143.

22. Dalley AJ, Pitty LP, Major AG, Abdulmajeed AA, Farah CS. Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma. Cancer Med. 2014;3(2):273-283.

23. Li DW, Tang HM, Fan JW, et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2010;136(7):997-1006.

24. Guo P, Gao A, Zhang G, Han H, Zhou Q. Decoding the knots of initiation of oncogenic epithelial-mesenchymal transition in tumor progression. Curr Cancer Drug Targets. 2013;13(9):996-1011.

25. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J, et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol. 2006;19(5):684-694.

26. Riis ML, Luders T, Nesbakken AJ, Vollan HS, Kristensen V, Buhkom IR. Expression of Bmi-1 and Mel-18 in breast tissue: a diagnostic marker in patients with breast cancer. BMC Cancer. 2010;10:686.

27. Guo BH, Zhang X, Zhang HZ, et al. Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Ann Oncol. 2010;21(12):2361-2369.

28. Wang W, Lin T, Huang J, Hu W, Xu K, Liu J. Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features. Urol Oncol. 2011;29(3):244-251.

29. Wang W, Yuasa T, Tsuchiya N, Hu W, Xu K, Liu J. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. Int J Cancer. 2009;125(12):2836-2843.

30. Alkema MJ, Wiegant J, Raak AP, Berns A, van Loohuizen M. Characterization and chromosomal localization of the human protooncogene Bmi-1. Hum Mol Genet. 1993;2(10):1597-1603.

31. Zhang Y, Zhang YL, Chen HM, et al. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma. World J Gastroenterol. 2014;20(18):5533-5539.

32. Liu WL, Guo XZ, Zhang LJ, et al. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer. 2010;10:467.

33. He XT, Cao XF, Ji L, et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol. 2009;15(19):2389-2394.

34. Hwang CC, Nieh S, Lai CH, et al. A retrospective study of the prognostic value of ALDH1, Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma. PLoS One. 2014;9(8): e105676.

35. Choy B, Bandla S, Xia Y, et al. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol. 2012;12:146.

36. Lee JY, Jang KS, Shin DH, et al. Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res. 2008;68(11):4201-4209.